{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:12:19Z","timestamp":1760425939608,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Zika virus (ZIKV) infections have been associated with an increased incidence of severe microcephaly and other neurodevelopmental disorders in newborn babies. Passive immunization with anti-ZIKV neutralizing antibodies has the potential to become a feasible treatment or prophylaxis option during pregnancy. Prior to clinical use, such antibodies should be assessed for their ability to block ZIKV passage to the fetus. We used human placental and mammalian cell monolayers that express FcRn and laboratory preparations of anti-ZIKV antibodies as a model system to investigate the disposition of ZIKV\/antibody immune complexes (ICs) at the maternal-fetal interface. We further characterized solution properties of the ICs to evaluate whether these are related to in vitro effects. We found that both ZIKV and ZIKV envelope glycoprotein can enter and passage through epithelial cells, especially those that overexpress FcRn. In the presence of ZIKV antibodies, Zika virus entry was bimodal, with reduced entry at the lowest (0.3\u20133 ng\/mL) and highest (\u00b5g\/mL) antibody concentrations. Intermediate concentrations attenuated inhibition or enhanced viral entry. With respect to anti-ZIKV antibodies, we found that their degradation was accelerated when presented as ICs containing increased amounts of ZIKV immunogen. Of the two monoclonal antibodies tested, the preparation with higher aggregation also exhibited higher degradation. Our studies confirm that intact Zika virus and its envelope immunogen have the potential to enter and be transferred across placental and other epithelial cells that express FcRn. Presence of anti-ZIKV IgG antibodies can either block or enhance cellular entry, with the antibody concentration playing a complex role in this process. Physicochemical properties of IgG antibodies can influence their degradation in vitro.<\/jats:p>","DOI":"10.3390\/vaccines9020145","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:12:10Z","timestamp":1613146330000},"page":"145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Entry and Disposition of Zika Virus Immune Complexes in a Tissue Culture Model of the Maternal-Fetal Interface"],"prefix":"10.3390","volume":"9","author":[{"given":"Yanqun","family":"Xu","sequence":"first","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaz","family":"Momben-Abolfath","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Eller","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Norton","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Scott","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evi Budo","family":"Struble","sequence":"additional","affiliation":[{"name":"Laboratory of Plasma Derivatives, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993-0002, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika Virus Associated with Microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sarno, M., Sacramento, G.A., Khouri, R., Ros\u00e1rio, M.S.D., Costa, F., Archanjo, G., Santos, L.A., Nery, N., Vasilakis, N., and Ko, A.I. (2016). Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004517"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2016.19006","article-title":"Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy","volume":"317","author":"Honein","year":"2017","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pattnaik, A., Sahoo, B.R., and Pattnaik, A.K. (2020). Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines, 8.","DOI":"10.3390\/vaccines8020266"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1172\/JCI139569","article-title":"SARS\u2013CoV-2 infection of the placenta","volume":"130","author":"Hosier","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chom.2018.10.008","article-title":"Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages","volume":"24","author":"Zimmerman","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1091\/mbc.e03-11-0832","article-title":"Bidirectional Transepithelial IgG Transport by a Strongly Polarized Basolateral Membrane Fc\u03b3-Receptor","volume":"15","author":"Claypool","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1385\/1-59259-989-3:225","article-title":"In Vitro Models for Studying Trophoblast Transcellular Transport","volume":"122","author":"Bode","year":"2006","journal-title":"Placenta Trophobl."},{"key":"ref_12","first-page":"425","article-title":"Structure of the thermally stable Zika virus","volume":"533","author":"Kostyuchenko","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cell.2019.04.035","article-title":"Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3201\/eid1408.080287","article-title":"Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007","volume":"14","author":"Lanciotti","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jmoldx.2019.06.004","article-title":"A Zika Reference Panel for Molecular-Based Diagnostic Devices as a US Food and Drug Administration Response Tool to a Public Health Emergency","volume":"21","author":"Sapsford","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"Neufeldt","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.meegid.2019.01.018","article-title":"ZIKA virus entry mechanisms in human cells","volume":"69","author":"Agrelli","year":"2019","journal-title":"Infect. Genet. Evol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/cti.2016.72","article-title":"Dengue virus antibodies enhance Zika virus infection","volume":"5","author":"Paul","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaav3208","DOI":"10.1126\/sciadv.aav3208","article-title":"Maternal immunity and antibodies to dengue virus promote infection and Zika virus\u2013induced microcephaly in fetuses","volume":"5","author":"Rathore","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_22","first-page":"1","article-title":"Differential cell line susceptibility to the emerging Zika virus: Implications for disease pathogenesis, non-vector-borne human transmission and animal reservoirs","volume":"5","author":"Chan","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Barr, K.L., Anderson, B.D., Prakoso, D., and Long, M.T. (2016). Working with Zika and Usutu Viruses in vitro. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004931"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2016.03.008","article-title":"Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection","volume":"19","author":"Bayer","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-019-1200-2","article-title":"Directional entry and release of Zika virus from polarized epithelial cells","volume":"16","author":"Tamhankar","year":"2019","journal-title":"Virol. J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., and Shi, Z. (2020). Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol., 94.","DOI":"10.1128\/JVI.02015-19"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"mAbs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/19420862.2019.1605270","article-title":"An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans","volume":"11","author":"Chung","year":"2019","journal-title":"mAbs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fimmu.2019.02049","article-title":"TRIM21\u2014From Intracellular Immunity to Therapy","volume":"10","author":"Foss","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:52Z","timestamp":1760160172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["vaccines9020145"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9020145","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}